EP4720109A1 - Récepteurs de lymphocytes t qui se lient à des peptides de hpv16, de mart1, de cmv, d'ebv ou de grippe présentés - Google Patents

Récepteurs de lymphocytes t qui se lient à des peptides de hpv16, de mart1, de cmv, d'ebv ou de grippe présentés

Info

Publication number
EP4720109A1
EP4720109A1 EP24734675.2A EP24734675A EP4720109A1 EP 4720109 A1 EP4720109 A1 EP 4720109A1 EP 24734675 A EP24734675 A EP 24734675A EP 4720109 A1 EP4720109 A1 EP 4720109A1
Authority
EP
European Patent Office
Prior art keywords
tcr
amino acid
cdr3
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24734675.2A
Other languages
German (de)
English (en)
Inventor
Lili BLUMENBERG
Raquel DEERING
Lianjie LI
Se JEONG
Stephane POURPE
Gavin Thurston
Johanna Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of EP4720109A1 publication Critical patent/EP4720109A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sont décrits dans la présente invention des récepteurs de lymphocytes T isolés qui se lient spécifiquement à un peptide de HPV16, de MART1, de CMV, d'EBV ou de grippe à présentation HLA, ainsi que des méthodes thérapeutiques et diagnostiques d'utilisation de ces TCR isolés.
EP24734675.2A 2023-05-25 2024-05-24 Récepteurs de lymphocytes t qui se lient à des peptides de hpv16, de mart1, de cmv, d'ebv ou de grippe présentés Pending EP4720109A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363504425P 2023-05-25 2023-05-25
US202363579554P 2023-08-30 2023-08-30
PCT/US2024/030997 WO2024243511A1 (fr) 2023-05-25 2024-05-24 Récepteurs de lymphocytes t qui se lient à des peptides de hpv16, de mart1, de cmv, d'ebv ou de grippe présentés

Publications (1)

Publication Number Publication Date
EP4720109A1 true EP4720109A1 (fr) 2026-04-08

Family

ID=91585365

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24734675.2A Pending EP4720109A1 (fr) 2023-05-25 2024-05-24 Récepteurs de lymphocytes t qui se lient à des peptides de hpv16, de mart1, de cmv, d'ebv ou de grippe présentés

Country Status (7)

Country Link
EP (1) EP4720109A1 (fr)
KR (1) KR20260016919A (fr)
CN (1) CN121335919A (fr)
AU (1) AU2024275280A1 (fr)
IL (1) IL324813A (fr)
MX (1) MX2025014061A (fr)
WO (1) WO2024243511A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120118176B (zh) * 2025-05-13 2025-07-18 北京立康生命科技有限公司 靶向afp肽的t细胞受体、其制备方法及伴随诊断试剂盒

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0400047B1 (fr) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Hepatocytes modifies et leurs utilisations
US5071743A (en) 1989-10-27 1991-12-10 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Process for conducting site-directed mutagenesis
EP0556345B2 (fr) 1990-10-31 2005-10-12 Cell Genesys, Inc. Vecteurs de retrovirus efficaces en therapie genique
JP3442774B2 (ja) 1991-07-01 2003-09-02 バーレックス ラボラトリーズ，インコーポレイティド 新規な突然変異誘発法および組成物
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6242222B1 (en) 1996-06-07 2001-06-05 Massachusetts Institute Of Technology Programmed sequential mutagenesis
US5780270A (en) 1996-07-17 1998-07-14 Promega Corporation Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
EP2486049A1 (fr) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Récepteurs de lymphocytes t à chaîne unique humains
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
IL252131B2 (en) 2014-11-17 2023-04-01 Adicet Bio Inc Transgenic gamma delta T cells
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
EP4324931A3 (fr) 2017-02-02 2024-05-29 New York Genome Center, Inc. Procédés et compositions pour identifier ou quantifier des cibles dans un échantillon biologique
JP7711049B2 (ja) 2019-10-03 2025-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 初代ヒト細胞における、同族ｔ細胞及びエピトープ反応性をスクリーニングするハイスループット法
WO2021158962A2 (fr) * 2020-02-06 2021-08-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Récepteurs de lymphocytes t ciblant des protéines de réparation d'adn défectueux
JP2024539291A (ja) * 2021-10-25 2024-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経膠芽腫を治療するための方法および組成物

Also Published As

Publication number Publication date
AU2024275280A1 (en) 2026-01-22
IL324813A (en) 2026-01-01
KR20260016919A (ko) 2026-02-04
CN121335919A (zh) 2026-01-13
WO2024243511A1 (fr) 2024-11-28
MX2025014061A (es) 2026-01-07
WO2024243511A9 (fr) 2025-12-11

Similar Documents

Publication Publication Date Title
AU2019331496B2 (en) Methods of making chimeric antigen receptor-expressing cells
AU2019364367B2 (en) NY-ESO-1 T cell receptors and methods of use thereof
JP7711049B2 (ja) 初代ヒト細胞における、同族ｔ細胞及びエピトープ反応性をスクリーニングするハイスループット法
US20230256017A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP7054397B2 (ja) Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
TW202134264A (zh) 嵌合抗原受體及其用途
WO2021150804A1 (fr) Antigène exprimé de préférence dans des récepteurs de lymphocytes t de mélanome (prame) et leurs procédés d'utilisation
US20250000973A1 (en) Methods of making chimeric antigen receptor-expressing cells
CN119907680A (zh) 使用嵌合抗原受体疗法的自身免疫性障碍的治疗
AU2024275280A1 (en) T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
US12630604B2 (en) Methods of making chimeric antigen receptor-expressing cells
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2025224438A1 (fr) Identification et fourniture de récepteur de lymphocytes t
HK40048881A (en) Methods of making chimeric antigen receptor-expressing cells
HK40048881B (en) Methods of making chimeric antigen receptor-expressing cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR